— Know what they know.
Not Investment Advice

PKI NYSE

PerkinElmer, Inc.
1W: +5.3% 1M: -10.8% 3M: -6.6% 1Y: -17.8% 3Y: +30.8% 5Y: +59.5%
$115.24
Last traded 2023-05-23 — delisted
NYSE · Healthcare · Medical - Diagnostics & Research · $14.5B mcap · 116M float · 0.699% daily turnover
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$14.5B
52W Range113.17-170.0
Volume1,633,024
Avg Volume811,897
Beta1.10
Dividend$0.28
Analyst Ratings
13 Buy 18 Hold 0 Sell
Consensus Hold
Company Info
CEOPrahlad R. Singh
Employees16,700
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date1983-04-06
940 Winter Street
Waltham, MA 02451
US
781 663 6900
About PerkinElmer, Inc.

PerkinElmer, Inc. operates as a global enterprise delivering innovative products, specialized services, and comprehensive solutions across the diagnostics, life sciences, and applied technology sectors. The company's operations are divided into two main segments: Discovery & Analytical Solutions, and Diagnostics. The Discovery & Analytical Solutions division furnishes scientists with an extensive suite of offerings, including chemical reagents, informatics platforms, and cutting-edge detection and imaging technologies. These resources are designed to accelerate research breakthroughs in the life sciences, and the segment also provides contract research and laboratory services. Additionally, it supplies analytical technologies, integrated solutions, and expert services to clients in the environmental, food, and industrial markets, aiding in the assessment and characterization of air, water, and soil quality. This segment further supports agricultural producers and food manufacturers, and delivers analytical instrumentation to a broad spectrum of industrial clients, encompassing chemical, semiconductor, electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment specializes in providing essential instruments, reagents, assay platforms, and software products for the early identification of genetic disorders, particularly during pregnancy and early childhood, as well as for infectious disease screening. Its product range facilitates the testing and detection of various genetic abnormalities and conditions, such as Down syndrome, hypothyroidism, muscular dystrophy, infertility, and diverse metabolic disorders. Moreover, this segment develops enabling technologies that support advanced genomic workflows, leveraging methods like G-protein coupled receptor (GPCR) analysis and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery research. PerkinElmer's client base is diverse, including pharmaceutical and biotechnology companies, research laboratories, academic and scientific institutions, public health organizations, private healthcare providers, medical professionals, and governmental agencies. Founded in 1937, PerkinElmer, Inc. is headquartered in Waltham, Massachusetts.

Latest News
No recent news

Recent Insider Trades

NameTypeSharesPriceDate
Gonzales Anita A-Award 248 2023-12-15
Gonzales Anita A-Award 706 $101.36 2023-12-15
MICHAS ALEXIS P G-Gift 230 2023-11-28
MICHAS ALEXIS P G-Gift 250 2023-11-27
Gonzales Anita A-Award 329 2023-06-15

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms